Pregnancy: Limited data — use only if risk is high.
Limited safety data for Ixiaro (inactivated Vero cell vaccine) in pregnancy.
Administer only if the risk of Japanese encephalitis exposure is judged to be high (prolonged rural travel during transmission season in endemic Asia).
No teratogenic effects reported in animal studies.
Live attenuated JE formulations (SA14-14-2, Imojev): contraindicated in pregnancy.
Defer vaccination until after delivery whenever possible.
Breastfeeding: Limited data — likely safe.
No formal studies of Ixiaro during breastfeeding. As an inactivated vaccine, it is unlikely to pose a risk to the breastfed infant. CDC considers inactivated vaccines generally acceptable during breastfeeding.
Pediatric use:
Ixiaro: licensed from 2 months of age.
Booster: 1 dose ≥1 year after primary series if ongoing exposure risk.
Live attenuated SA14-14-2 (in endemic countries): single dose from 8 months of age.
Geriatric use:
No specific dose adjustment required.
Immune response may be slightly lower in elderly adults — consider booster if ongoing exposure risk.
Japanese encephalitis is more severe in older adults (higher case-fatality rate in ≥65 years).
Standard 2-dose Ixiaro schedule applies.
Hakuna data ya ratiba inayopatikana.
Unajua chanjo unayohitaji? Vizuri. Hujui? Tuambie tu unaenda wapi — tutapata chanjo zinazofaa na kliniki. Bure, bila masharti.
Maudhui katika ukurasa huu ni kwa madhumuni ya habari na elimu pekee. Hayaundi ushauri wa kitabibu, utambuzi, au mapendekezo ya matibabu. Ikiwa una wasiwasi wa kiafya, wasiliana na mtaalamu wa afya aliyeidhinishwa. Medova si mtoa huduma za matibabu.
Masharti kamili ya matumizi